Literature DB >> 19933310

Dissection of platelet and myeloid cell defects by conditional targeting of the beta3-integrin subunit.

Elizabeth A Morgan1, Jochen G Schneider, Timothy E Baroni, Ozge Uluçkan, Emanuela Heller, Michelle A Hurchla, Hongju Deng, Desiree Floyd, Andrew Berdy, Julie L Prior, David Piwnica-Worms, Steven L Teitelbaum, F Patrick Ross, Katherine N Weilbaecher.   

Abstract

The purpose of this work was to determine platelet and myeloid cell-specific requirements for beta3-containing integrins in hemostasis, bone resorption, and tumor growth. LoxP-flanked mice were generated to study the conditional deletion of beta3-integrin in platelets [knockout in platelets (KOP)] and myeloid cells [knockout in myeloid (KOM)]. Using the beta3KOP and beta3KOM strains of mice, we studied the role of beta3-integrin in hemostasis, bone resorption, and subcutaneous tumor growth. Tissue-specific deletion of platelet beta3-integrins in beta3KOP mice did not affect bone mass but resulted in a severe bleeding phenotype. No growth difference of tumor xenografts or in neoangiogenesis were found in beta3KOP mice, in contrast to the defects observed in germline beta3(-/-) mice. Conditional deletion of myeloid beta3-integrins in beta3KOM mice resulted in osteopetrosis but had no effect on hemostasis or mortality. Tumor growth in beta3KOM mice was increased and accompanied by decreased macrophage infiltration, without increase in blood vessel number. Platelet beta3-integrin deficiency was sufficient to disrupt hemostasis but had no effect on bone mass or tumor growth. Myeloid-specific beta3-integrin deletion was sufficient to perturb bone mass and enhance tumor growth due to reduced macrophage infiltration in the tumors. These results suggest that beta3-integrins have cell-specific roles in complex biological processes.-Morgan, E. A., Schneider, J. G., Baroni, T. E., Uluçkan, O., Heller, E., Hurchla, M. A., Deng, H., Floyd, D., Berdy, A., Prior, J. L., Piwnica-Worms, D., Teitelbaum, S. L., Ross, F. P., Weilbaecher, K. N. Dissection of platelet and myeloid cell defects by conditional targeting of the beta3-integrin subunit.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19933310      PMCID: PMC2845430          DOI: 10.1096/fj.09-138420

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  50 in total

1.  Glucocorticoids suppress bone formation via the osteoclast.

Authors:  Hyun-Ju Kim; Haibo Zhao; Hideki Kitaura; Sandip Bhattacharyya; Judson A Brewer; Louis J Muglia; F Patrick Ross; Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2006-07-27       Impact factor: 14.808

2.  Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner.

Authors:  Angela C Hirbe; Ozge Uluçkan; Elizabeth A Morgan; Mark C Eagleton; Julie L Prior; David Piwnica-Worms; Kathryn Trinkaus; Anthony Apicelli; Katherine Weilbaecher
Journal:  Blood       Date:  2006-12-27       Impact factor: 22.113

3.  Intracranial microenvironment reveals independent opposing functions of host alphaVbeta3 expression on glioma growth and angiogenesis.

Authors:  Masayuki Kanamori; Tomohiro Kawaguchi; Mitchel S Berger; Russell O Pieper
Journal:  J Biol Chem       Date:  2006-10-06       Impact factor: 5.157

4.  Beta3 integrin deficiency promotes cardiac hypertrophy and inflammation.

Authors:  Jie Ren; Joan Avery; Haibo Zhao; Jochen G Schneider; F Patrick Ross; Anthony J Muslin
Journal:  J Mol Cell Cardiol       Date:  2006-12-20       Impact factor: 5.000

5.  Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo.

Authors:  Ralph Tiedt; Tibor Schomber; Hui Hao-Shen; Radek C Skoda
Journal:  Blood       Date:  2006-10-10       Impact factor: 22.113

6.  Regulated expression of platelet factor 4 in human monocytes--role of PARs as a quantitatively important monocyte activation pathway.

Authors:  Andreas Schaffner; Petra Rhyn; Gabriela Schoedon; Dominik J Schaer
Journal:  J Leukoc Biol       Date:  2005-03-23       Impact factor: 4.962

7.  Increased glioma growth in mice depleted of macrophages.

Authors:  Hugo Galarneau; Jérôme Villeneuve; Geneviève Gowing; Jean-Pierre Julien; Luc Vallières
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

8.  Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin.

Authors:  P S Frenette; R C Johnson; R O Hynes; D D Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

9.  Macrophage beta3 integrin suppresses hyperlipidemia-induced inflammation by modulating TNFalpha expression.

Authors:  Jochen G Schneider; Yimin Zhu; Trey Coleman; Clay F Semenkovich
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-10-19       Impact factor: 8.311

10.  Integrin signaling is critical for pathological angiogenesis.

Authors:  Ganapati H Mahabeleshwar; Weiyi Feng; David R Phillips; Tatiana V Byzova
Journal:  J Exp Med       Date:  2006-10-09       Impact factor: 14.307

View more
  25 in total

1.  C560Rβ3 caused platelet integrin αII b β3 to bind fibrinogen continuously, but resulted in a severe bleeding syndrome and increased murine mortality.

Authors:  J Fang; P Nurden; P North; A T Nurden; L M Du; N Valentin; D A Wilcox
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

2.  Novel Pure αVβ3 Integrin Antagonists That Do Not Induce Receptor Extension, Prime the Receptor, or Enhance Angiogenesis at Low Concentrations.

Authors:  Jihong Li; Yoshiyuki Fukase; Yi Shang; Wei Zou; José M Muñoz-Félix; Lorena Buitrago; Johannes van Agthoven; Yixiao Zhang; Ryoma Hara; Yuta Tanaka; Rei Okamoto; Takeshi Yasui; Takashi Nakahata; Toshihiro Imaeda; Kazuyoshi Aso; Yuchen Zhou; Charles Locuson; Dragana Nesic; Mark Duggan; Junichi Takagi; Roger D Vaughan; Thomas Walz; Kairbaan Hodivala-Dilke; Steven L Teitelbaum; M Amin Arnaout; Marta Filizola; Michael A Foley; Barry S Coller
Journal:  ACS Pharmacol Transl Sci       Date:  2019-08-02

3.  Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment.

Authors:  Emanuela Heller; Michelle A Hurchla; Jingyu Xiang; Xinming Su; Sara Chen; Jochen Schneider; Kyu-Sang Joeng; Marcos Vidal; Leah Goldberg; Hongju Deng; Mary C Hornick; Julie L Prior; David Piwnica-Worms; Fanxin Long; Ross Cagan; Katherine N Weilbaecher
Journal:  Cancer Res       Date:  2011-12-20       Impact factor: 12.701

4.  Podocyte Integrin-β 3 and Activated Protein C Coordinately Restrict RhoA Signaling and Ameliorate Diabetic Nephropathy.

Authors:  Thati Madhusudhan; Sanchita Ghosh; Hongjie Wang; Wei Dong; Dheerendra Gupta; Ahmed Elwakiel; Stoyan Stoyanov; Moh'd Mohanad Al-Dabet; Shruthi Krishnan; Ronald Biemann; Sumra Nazir; Silke Zimmermann; Akash Mathew; Ihsan Gadi; Rajiv Rana; Jinyang Zeng-Brouwers; Marcus J Moeller; Liliana Schaefer; Charles T Esmon; Shrey Kohli; Jochen Reiser; Alireza R Rezaie; Wolfram Ruf; Berend Isermann
Journal:  J Am Soc Nephrol       Date:  2020-07-24       Impact factor: 10.121

5.  Thrombospondin-1 regulates bone homeostasis through effects on bone matrix integrity and nitric oxide signaling in osteoclasts.

Authors:  Sarah R Amend; Ozge Uluckan; Michelle Hurchla; Daniel Leib; Deborah Veis Novack; Matthew Silva; William Frazier; Katherine N Weilbaecher
Journal:  J Bone Miner Res       Date:  2015-01       Impact factor: 6.741

6.  The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling.

Authors:  Xinming Su; Desiree H Floyd; Alun Hughes; Jingyu Xiang; Jochen G Schneider; Ozge Uluckan; Emanuela Heller; Hongju Deng; Wei Zou; Clarissa S Craft; Kaiming Wu; Angela C Hirbe; Dorota Grabowska; Mark C Eagleton; Sarah Townsley; Lynne Collins; David Piwnica-Worms; Thomas H Steinberg; Deborah V Novack; Pamela B Conley; Michelle A Hurchla; Michael Rogers; Katherine N Weilbaecher
Journal:  J Clin Invest       Date:  2012-09-17       Impact factor: 14.808

Review 7.  Integrins and bone metastasis: integrating tumor cell and stromal cell interactions.

Authors:  Jochen G Schneider; Sarah R Amend; Katherine N Weilbaecher
Journal:  Bone       Date:  2010-09-17       Impact factor: 4.398

8.  Bone-Induced Expression of Integrin β3 Enables Targeted Nanotherapy of Breast Cancer Metastases.

Authors:  Michael H Ross; Alison K Esser; Gregory C Fox; Anne H Schmieder; Xiaoxia Yang; Grace Hu; Dipanjan Pan; Xinming Su; Yalin Xu; Deborah V Novack; Thomas Walsh; Graham A Colditz; Gabriel H Lukaszewicz; Elizabeth Cordell; Joshua Novack; James A J Fitzpatrick; David L Waning; Khalid S Mohammad; Theresa A Guise; Gregory M Lanza; Katherine N Weilbaecher
Journal:  Cancer Res       Date:  2017-08-30       Impact factor: 12.701

9.  αvβ3 Integrins Mediate Flow-Induced NF-κB Activation, Proinflammatory Gene Expression, and Early Atherogenic Inflammation.

Authors:  Jie Chen; Jonette Green; Arif Yurdagul; Patrick Albert; Marshall C McInnis; A Wayne Orr
Journal:  Am J Pathol       Date:  2015-07-26       Impact factor: 4.307

Review 10.  Glanzmann thrombasthenia: state of the art and future directions.

Authors:  Alan T Nurden; Xavier Pillois; David A Wilcox
Journal:  Semin Thromb Hemost       Date:  2013-08-08       Impact factor: 4.180

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.